AxoGen (NASDAQ:AXGN) releases earnings results, beats expectations by $0.08 EPS. AxoGen (NASDAQ:AXGN - Get Free Report) posted its quarterly earnings results on Wednesday. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.08, FiscalAI reports. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.18 million. Here are the key takeaways from AxoGen's conference call: * Positive Sentiment: AxoGen reported third-quarter revenue of $75.8 million, up 26.2% year over year, with breast revenue increasing more than 60% and adjusted EBITDA rising 46% to $13.4 million. Management raised 2026 guidance to at least $290 million in revenue, including $7 million from BioCircuit, while maintaining expectations for at least 73% gross margin and positive free cash flow. * Positive Sentiment: Commercial payer coverage for Avance reached approximately 96% of U.S. covered lives after Elevance removed its nerve-gap restriction and Aetna added coverage for certain upper-extremity repairs. The company said breast growth is supported by expanding account adoption, with roughly 485 active breast accounts and 590 active surgeons. * Positive Sentiment: AxoGen completed its $200 million BioCircuit acquisition, adding NerveTape and access to direct nerve-repair procedures representing an estimated 40%-50% of transected nerve cases. Management expects the product to contribute to revenue growth and adjusted EBITDA margin in its first year, although integration and potential cannibalization risks remain. * Negative Sentiment: Gross margin declined to 74.8% from 76.6% a year earlier and is expected to decrease sequentially in the fourth quarter as production shifts toward longer Avance grafts for breast procedures. The company also warned that BioCircuit purchase-accounting inventory adjustments could further pressure fourth-quarter and full-year gross margin, while higher amortization and administrative expenses are expected going forward. * Positive Sentiment: AxoGen plans to begin prostate nerve-reconstruction market development in 2027 after treating more than 220 patients across 15 sites; among patients with at least six months of follow-up, surgeons reported better-than-expected erectile-function recovery in approximately 80% and pad-free urinary continence above expected levels in more than 95%. Prostate is not included in current guidance, but management views it as a potentially meaningful long-term growth driver. AxoGen trading up 31.7%. NASDAQ AXGN traded up $11.87 during trading hours on Wednesday, hitting $49.33. The company's stock had a trading volume of 4,459,978 shares, compared to its average volume of 1,170,102. The stock has a fifty day moving average of $42.80 and a 200 day moving average of $39.20. AxoGen has a twelve month low of $18.46 and a twelve month high of $52.91. Analyst ratings changes. AXGN has been the subject of several recent analyst reports. Wall Street Zen downgraded AxoGen from a "buy" rating to a "hold" rating in a research report on Saturday, September 26th. Lake Street Capital restated a "buy" rating on shares of AxoGen in a research report on Monday, October 5th. Citizens Jmp lifted their price objective on shares of AxoGen from $50.00 to $55.00 and gave the company a "market outperform" rating in a report on Thursday, July 30th. Citigroup reaffirmed a "market outperform" rating on shares of AxoGen in a report on Thursday, July 30th. Finally, Bank of America began coverage on shares of AxoGen in a report on Monday, October 12th. They set a "buy" rating and a $52.00 price objective on the stock. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, AxoGen has an average rating of "Moderate Buy" and a consensus price target of $51.27. Insider buying and selling at AxoGen. In related news, Director Amy Wendell sold 13,353 shares of AxoGen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total transaction of $646,552.26. Following the completion of the sale, the director directly owned 107,976 shares of the company's stock, valued at $5,228,197.92. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total value of $3,195,450.00. Following the completion of the transaction, the executive vice president directly owned 50,135 shares in the company, valued at $2,373,390.90. The trade was a 57.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 98,503 shares of company stock worth $4,656,947 over the last quarter. 2.44% of the stock is currently owned by insiders. About AxoGen. AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves. The company's product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient's body. Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Axogen closes $200M BioCircuit deal, adding first sutureless nerve-repair device. Published on October 05, 2026 Axogen has finalized its $200 million acquisition of BioCircuit Technologies, a privately held medical device maker whose flagship product, NerveTape, is billed as the first FDA-cleared sutureless device for repairing severed peripheral nerves. The deal closed October 1, bringing a new surgical tool into the hands of a company that already bills itself as a global leader in restoring peripheral nerve function. Axogen first announced the agreement on September 10, saying it had entered into a definitive deal to acquire BioCircuit for $200 million in cash at closing, subject to customary adjustments, according to Axogen investor relations. At the time, the company said it expected the transaction to close in the fourth quarter, with the deal contingent on customary closing conditions, including completion of BioCircuit's electronics business spin-out. The agreement had already been approved by the boards of directors of both companies, per the same filing. The acquisition closed faster than the original fourth-quarter timeline suggested, with Axogen confirming completion on October 1, as reported by BioSpace. BioCircuit, based in Atlanta, Georgia, develops and commercializes medical devices for peripheral nerve repair and neuromodulation, the outlet noted. NerveTape, the company's signature device, is designed to simplify and enhance peripheral nerve repair procedures for surgeons treating transected nerves. What the deal means for Axogen's bottom line. Axogen expects BioCircuit to contribute roughly $6 million in fourth-quarter 2026 revenue and approximately $34 million in 2027 revenue, according to a report from Quiver Quant. That projected contribution was not part of the full-year 2026 guidance Axogen had most recently issued, which called for at least 24% revenue growth, the outlet noted. The company said it continues to expect gross margin of at least 73% and to remain free cash positive for the full year. Axogen had also said the deal is expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted earnings per share within the first year after closing, while the company maintains positive free cash flow, per Axogen investor relations. Taken together, the figures suggest Axogen is betting NerveTape can scale quickly inside its existing surgical sales channels rather than simply adding a one-off product line. Foley Hoag's role in closing the deal. The law firm Foley Hoag served as legal advisor to Axogen throughout the transaction, a role the firm detailed in its own account of the deal published Friday. Foley Hoag said its deal team was led by partner Mark Haddad of the firm's Boston office, with partners Earl Mellott, Allison Anderson, John Harre, Janine Ladislaw, and Barbara Klepper also involved, according to Foley Hoag. Associates Nitzan Fisher Conforti, Lee Ramati, Ariel Chen, Hannah Melville, and Alexandra Levay rounded out the team, the firm said, drawing on attorneys based in its Boston, New York, and Washington, D.C. offices. Axogen, which trades on the Nasdaq under the ticker AXGN, describes itself as a global leader in developing and marketing surgical solutions for the restoration of peripheral nerve function. With NerveTape now folded into its portfolio, the company has expanded its lineup of nerve repair technologies beyond the suture-based approaches that have long defined the field. A new option for nerve repair surgery. What makes NerveTape notable to surgeons is its sutureless approach. Rather than requiring stitches to rejoin a severed nerve, the device is positioned as a faster, simpler alternative, an incremental but meaningful shift for operating rooms handling peripheral nerve injuries. A U.S. Food and Drug Administration clearance document for the device describes it as indicated for repair of peripheral nerve discontinuities where gap closure can be achieved by flexion, though the publicly available excerpt of that filing cuts off before detailing the rest of the indication's full scope. For now, the deal's immediate impact is financial and strategic: Axogen gains a cleared device with projected near-term revenue, while BioCircuit's technology moves from a privately held startup into the hands of a Nasdaq-listed company with an established surgical sales network. Whether NerveTape reshapes nerve repair surgery as broadly as its first-of-its-kind FDA clearance suggests will likely play out over the next several fiscal quarters, as Axogen's own revenue projections for 2027 come into focus.

Nasdaq Composite surges on tech strength while (NYSE: RTX), (NASDAQ: IART), (NASDAQ: PECO) and (NASDAQ: AXGN) make market moves. Big technology drove the Nasdaq Composite to a weekly gain as the Dow Jones Industrial Average and Russell 2000 both closed the week in negative territory. The Nasdaq Composite jumped 1.18% on the day to close at 27,188.02, posting a weekly gain of 0.44% as chip and software names led the advance. The Dow Jones Industrial Average finished at 51,094.96, up 0.33% on the day but down 1.42% for the week, with an RSI14 of 38.1 signaling a weakening trend. The S&P 500 settled at 7,719.34, gaining 0.69% on Friday but slipping 0.31% for the week, while the Russell 2000 rose 0.97% on the day to 2,833.74 but edged down 0.13% for the week. The CBOE Volatility Index fell to 15.58, down 0.81 on the day, while WTI crude oil dropped 2.48% on the day and 2.19% for the week to settle at $90.57 a barrel. Gold eased 0.85% on the day to $4,166.60 an ounce, silver fell to $60.40, and the US 10-year Treasury yield rose 8 basis points for the week to 5.26%. RTX (NYSE: RTX) saw its Raytheon division secure a five-year contract with two additional option years valued at up to $24.4 billion for Standard Missile-6 interceptors for the U.S. Navy. Phil Jasper, Raytheon President, said: "SM-6's multi-mission capability is vital to our customer, and Raytheon is intensely focused on meeting the demand." Integra LifeSciences Holdings Corporation (NASDAQ: IART) provided preliminary third-quarter results, citing ongoing impact from a July flooding event at its Cincinnati facility, with expected revenue of approximately $410 million to $412 million. Stuart Essig, Chairman and Chief Executive Officer, said: "Our third quarter results were impacted by the July flooding event at our Cincinnati facility. Our teams have made significant progress executing recovery plans and supporting customers." IART lowered its full-year 2026 revenue outlook to $1.634 billion to $1.654 billion and cut adjusted EPS guidance to $2.30 to $2.40, while still targeting $190 million to $200 million in operating cash flow. Trilogy Metals Inc. (NYSE American: TMQ) reported a cash balance of $31.2 million as of August 31, 2026, and announced the closing of a $35.6 million strategic equity investment from the Department of War on September 11, 2026. Tony Giardini, President and CEO of Trilogy Metals, said: "The third quarter and the weeks that followed have been transformational for Trilogy Metals." Phillips Edison and Company, Inc. (NASDAQ: PECO) reaffirmed its full-year 2026 earnings guidance and raised its gross acquisitions target to $600 million to $700 million after acquiring $459.7 million in assets year to date through September 30, 2026. Jeff Edison, Chairman and Chief Executive Officer, said: "We're pleased to reaffirm our guidance for full year 2026 Core FFO per share growth, which reflects 6.2% year-over-year growth at the midpoint." Axogen, Inc. (NASDAQ: AXGN) completed its acquisition of BioCircuit Technologies, adding NerveTape, described as the first FDA cleared device for sutureless peripheral nerve repair. Michael Dale, President and Chief Executive Officer of Axogen, said: "NerveTape represents a new standard of care as the first sutureless nerve repair option, one that is simpler, faster, and more effective than microsuturing." Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue, with the company maintaining its full-year 2026 guidance of at least 24% revenue growth.